Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Fortress Biotech stock

FBIO
US34960Q1094
A14SJV

Price

0
Today +/-
-0
Today %
-0 %
P

Fortress Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Fortress Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Fortress Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Fortress Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Fortress Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Fortress Biotech Stock Price History

DateFortress Biotech Price
10/4/20240 undefined
10/3/20240 undefined
10/2/20240 undefined
10/1/20240 undefined
9/30/20240 undefined
9/27/20240 undefined
9/26/20240 undefined
9/25/20240 undefined
9/24/20240 undefined
9/23/20240 undefined
9/20/20240 undefined
9/19/20240 undefined
9/18/20240 undefined
9/17/20240 undefined
9/16/20240 undefined
9/13/20240 undefined
9/12/20240 undefined
9/11/20240 undefined
9/10/20240 undefined
9/9/20240 undefined
9/6/20240 undefined

Fortress Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fortress Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fortress Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fortress Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fortress Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fortress Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fortress Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fortress Biotech’s growth potential.

Fortress Biotech Revenue, EBIT and net profit per share

DateFortress Biotech RevenueFortress Biotech EBITFortress Biotech Net Income
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Fortress Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00000000161726364568758483151193199680721725
---------6.2552.9438.4625.0051.1110.2912.00-1.1981.9327.813.11241.716.030.55
--------93.7576.4776.9272.2268.8952.9458.6767.86-------
0000000015132026313644570000000
-3-2-9-35-27-35-20-50-65-89-120-110-94-179-203-139-137-108-89-1131804075
---------406.25-523.53-461.54-305.56-208.89-263.24-270.67-165.48-165.06-71.52-46.11-56.7826.475.5510.34
-3-3-9-42-27-37-20-48-55-66-84-39-46-64-86-68-104-61-480000
--200.00366.67-35.7137.04-45.95140.0014.5820.0027.27-53.5717.9539.1334.38-20.9352.94-41.35-21.31----
1.241.241.240.511.442.032.422.612.662.782.93.654.85.455.938.110000000
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Fortress Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Fortress Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200920102011201220132014201520162017201820192020202120222023
                             
1.514.923.240.299.569.898.290.713183.1136.9233.4305.7178.380.93
00000001.87.85.513.523.923.128.215.22
0000000.26.90.62.10.90.80.70.10.17
00000000.20.20.70.91.49.914.210.21
00.10.20.40.50.71.610.143.619.84.16.77.19.710.5
1.51523.440.610070.5100109.7183.2111.2156.3266.2346.5230.5117.02
0000.10.40.10.37.47.11233.932.434.13323.5
000004.22.51.41.4011.117.6000
000000000000000
0000001.317.40.91.47.414.612.627.220.29
000000018.60000000
0.2000.30.114.714.616.353.416.417.72.73.43.76.72
0.2000.40.51918.761.162.829.870.167.350.163.950.5
1.71523.441100.589.5118.7170.8246141226.4333.5396.6294.4167.53
                             
029.30000000.60.70.60.10.10.10.02
0.14.375.7106.2202.6212.2247283.7364.1397.4461.9583656675.8717.4
-10.2-20.2-56.6-84.2-121.3-141.7-190.2-245.3-312.1-396.3-436.2-482.8-547.5-634.2-694.87
000000000000000
000000000000000
-10.113.419.12281.370.556.838.452.61.826.3100.3108.641.722.54
0.60.50.610.50.41.924.327.634.222.928.567.477.153.03
1.612.92.34.53.78.11211.315.518.625.322.823.06
0000000.618.329.6100.13.820.65.82
900000000000000
0001.86.200213.219.17.24.54.57.23
11.21.53.55.111.24.110.656.671.455.645.651.7101127.784.91
0.600.812.471423.226.249.360.482.459.846.693.160.86
000000000000000
0001.41.10.70.654.75.225.824.82323.420.18
0.600.813.88.114.723.831.25465.6108.284.669.6116.581.03
11.81.54.318.919.318.834.487.8125.4121.2153.8136.3170.6244.2165.94
1.714.923.440.9100.689.391.2126.2178123180.1236.6279.2285.9188.48
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Fortress Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Fortress Biotech's financial health and stability.

Assets

Fortress Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Fortress Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Fortress Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Fortress Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2008200920102011201220132014201520162017201820192020202120222023
-3-3-9-36-27-37-20-53-71-99-141-101-102-164-213-154
0000000011233575
0000000000000000
000101-152-35-4-4360-12
013234652822213582062732
0000010000458697
0000000000000000
-3-2-5-10-23-29-16-20-45-81-98-94-83-116-179-128
000-3000-1-6-4-8-4-3-4-2-5
000-300-237-6-401820-740-22-2
000000-2390-362724-445-202
0000000000000000
340013-1096371615-29-644-39
0021252890400251558167442576
3319234089-106042150501461721487532
00-2-2-20-14513688207641119144
0000000000-2-2-6-8-8-8
011381759-4948-828-29718172-127-97
-3.52-2.35-5.69-14.79-23.24-29.69-16.33-21.91-52.53-85.32-107.13-99.71-86.81-121.51-182.12-133.29
0000000000000000

Fortress Biotech stock margins

The Fortress Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fortress Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fortress Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fortress Biotech's sales revenue. A higher gross margin percentage indicates that the Fortress Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fortress Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fortress Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fortress Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fortress Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fortress Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fortress Biotech Margin History

Fortress Biotech Gross marginFortress Biotech Profit marginFortress Biotech EBIT marginFortress Biotech Profit margin
2030e0 %0 %0 %
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %

Fortress Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Fortress Biotech earnings per share therefore indicates how much revenue Fortress Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fortress Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fortress Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fortress Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fortress Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fortress Biotech Revenue, EBIT and net profit per share

DateFortress Biotech Sales per ShareFortress Biotech EBIT per shareFortress Biotech Earnings per Share
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Fortress Biotech business model

Fortress Biotech Inc was founded in 2006 and is headquartered in New York City. The company specializes in the development of therapies for serious diseases and operates under a cooperative business model. The business model of Fortress Biotech is based on having multiple subsidiary companies under its umbrella, each focusing on specific development programs. This allows for specialized coverage of every aspect of the development process, from basic research to clinical trials to drug approval by authorities, by each subsidiary. Fortress Biotech has a total of nine subsidiary companies, each conducting its own research and development programs. These programs mainly target cancer, rare diseases, and metabolic disorders. With its various subsidiary companies, the company is able to develop and manufacture a wide range of therapeutic solutions. One of Fortress Biotech's most well-known subsidiary companies is Mustang Bio, a biotechnology company focusing on the development of immune-based therapies for cancer patients. The company has developed a promising CAR-T cell therapy that is currently being studied in clinical trials. Another subsidiary company of Fortress Biotech is Caelum Biosciences, which develops therapies for hematological diseases. The company is currently working on a promising monoclonal antibody therapy to help patients with the rare disease AL amyloidosis. In addition to its subsidiary companies, Fortress Biotech also collaborates with other companies and academic institutions to develop innovative therapies. The company has partnerships with companies such as Kadmon Holdings, Inc. and Aevi Genomic Medicine, Inc. Fortress Biotech has had an impressive growth story in recent years. Through targeted acquisitions of companies with promising product pipelines, the company has been able to rapidly progress and expand its offering of therapeutic solutions. In summary, Fortress Biotech is a promising biotechnology company specializing in the development of therapies for serious diseases. With its cooperative business model, wide range of subsidiary companies, and partnerships, the company is able to develop and bring innovative therapy solutions to market to help patients worldwide. Fortress Biotech is one of the most popular companies on Eulerpool.com.

Fortress Biotech SWOT Analysis

Strengths

Fortress Biotech Inc. has a strong portfolio of innovative biopharmaceutical products with potential for significant market growth. The company's diverse pipeline includes promising candidates in various stages of clinical development.

Fortress Biotech benefits from strategic partnerships and collaborations with leading academic institutions, research organizations, and pharmaceutical companies, which enhances its research capabilities and increases the likelihood of successful drug development.

The company has a well-established track record of successfully advancing compounds through clinical trials and obtaining regulatory approvals. Fortress Biotech's experience and expertise in navigating the regulatory landscape give it a competitive advantage.

Weaknesses

Fortress Biotech heavily relies on external sources of funding, such as venture capital, for its operations and research activities. This dependence on external financing may pose risks and uncertainties, especially in a volatile market.

The company's current portfolio is predominantly focused on early-stage candidates, which carry higher risks compared to late-stage or commercialized products. The prolonged and uncertain timeline for clinical development and regulatory approval could hinder revenue generation and financial stability.

Fortress Biotech's relatively small size and limited resources may limit its ability to effectively compete with larger pharmaceutical companies that have greater financial and marketing resources.

Opportunities

The biopharmaceutical industry is experiencing rapid growth driven by technological advancements, increasing healthcare expenditure, and a growing global population. Fortress Biotech can capitalize on these trends by expanding its product portfolio and targeting unmet medical needs.

The company has the opportunity to explore global markets and partnerships to enhance its market presence. Collaborations with international pharmaceutical companies or entry into emerging markets can facilitate access to a wider patient population and drive revenue growth.

The rising demand for personalized medicine and targeted therapies presents an opportunity for Fortress Biotech to leverage its expertise in precision medicine and develop novel treatments tailored to specific patient populations.

Threats

The highly competitive nature of the biopharmaceutical industry poses a threat to Fortress Biotech's market position. Competition can come from larger pharmaceutical companies, innovative startups, or generic drug manufacturers, potentially impacting market share and profitability.

External factors such as changes in government regulations, healthcare policies, or reimbursement systems can significantly impact the company's operations and financial performance. Adapting to evolving regulatory frameworks and maintaining compliance is imperative.

The unpredictability of clinical trials and drug development carries inherent risks. Uncertainties related to safety, efficacy, and unforeseen adverse events could lead to trial failures or regulatory setbacks, adversely affecting Fortress Biotech's reputation and financial viability.

Fortress Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Fortress Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Fortress Biotech shares outstanding

The number of shares was Fortress Biotech in 2023 — This indicates how many shares 8.111 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fortress Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fortress Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fortress Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fortress Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fortress Biotech stock splits

In Fortress Biotech's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Fortress Biotech.

Fortress Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (41.5 %)2024 Q2
3/31/20240 0  (41.63 %)2024 Q1
12/31/20230 0  (36.19 %)2023 Q4
9/30/20230 0  (71.25 %)2023 Q3
6/30/20230 0  (-3.42 %)2023 Q2
3/31/20230 0  (-2.94 %)2023 Q1
12/31/20220 0  (-29.57 %)2022 Q4
9/30/20220 0  (9.22 %)2022 Q3
6/30/20220 0  (-12.04 %)2022 Q2
3/31/20220 0  (36.97 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Fortress Biotech stock

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

38

👫 Social

19

🏛️ Governance

43

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fortress Biotech shareholders

%
Name
Stocks
Change
Date
5.90524 % Weiss (Michael S)1,346,98503/27/2024
3.35181 % Heights Capital Management, Inc.764,549764,54912/31/2023
2.66461 % Rosalind Advisors, Inc.607,797607,79712/31/2023
2.61289 % Armistice Capital LLC596,000596,00012/31/2023
12.55548 % Rosenwald (Lindsay A)2,863,90503/27/2024
1.77607 % Altium Capital Management LP405,122405,12212/31/2023
1.76910 % Dak Capital Inc403,532403,5322/10/2023
1.63333 % Nantahala Capital Management, LLC372,562-28,65212/31/2023
1.55148 % The Vanguard Group, Inc.353,8933,32312/31/2023
1.43461 % Hudson Bay Capital Management LP327,235327,23512/31/2023
1
2
3
4
5
...
10

Fortress Biotech Executives and Management Board

Dr. Lindsay Rosenwald67
Fortress Biotech Executive Chairman of the Board, President, Chief Executive Officer (since 2009)
Compensation 1.74 M
Mr. David Jin33
Fortress Biotech Chief Financial Officer, Corporate Secretary
Compensation 1.47 M
Mr. Michael Weiss57
Fortress Biotech Executive Vice Chairman - Strategic Development, Director (since 2013)
Compensation 966,566
Dr. Lucy Lu48
Fortress Biotech Independent Director (since 2012)
Compensation 576,272
Dr. Eric Rowinsky66
Fortress Biotech Co-Vice Chairman of the Board (since 2010)
Compensation 479,250
1
2
3

Most common questions regarding Fortress Biotech

What values and corporate philosophy does Fortress Biotech represent?

Fortress Biotech Inc represents values of innovation, collaboration, and dedication to improving patients' lives. With a corporate philosophy focused on advancing and commercializing novel therapies, the company aims to address unmet medical needs in various therapeutic areas. Fortress Biotech Inc fosters strategic partnerships and leverages its diverse and experienced team to develop cutting-edge treatments. By nurturing a culture of excellence and a commitment to delivering value to stakeholders, Fortress Biotech Inc aims to be at the forefront of healthcare innovation.

In which countries and regions is Fortress Biotech primarily present?

Fortress Biotech Inc primarily operates in the United States.

What significant milestones has the company Fortress Biotech achieved?

Fortress Biotech Inc has achieved several significant milestones in its journey. The company has successfully advanced multiple clinical programs, including the FDA approval of its targeted therapy for a certain type of lymphoma. Additionally, Fortress Biotech has established strategic collaborations with renowned pharmaceutical companies to further develop its innovative pipeline and expand its global reach. With a strong focus on research and development, Fortress Biotech has also made notable progress in advancing novel therapies for rare diseases, oncology, and dermatology. Overall, the company's dedication to scientific excellence and strategic partnerships has propelled it to achieve noteworthy milestones in the biotech industry.

What is the history and background of the company Fortress Biotech?

Fortress Biotech Inc is a renowned biopharmaceutical company with a rich history and remarkable background. Founded in 2006, the company focuses on acquiring, developing, and commercializing various innovative pharmaceutical and biotechnology products. Fortress Biotech Inc operates through a unique business model, collaborating with a diverse network of partner companies to advance a wide range of therapeutic areas. With a strong commitment to improving patients' lives, the company's robust pipeline includes treatments for rare diseases, dermatology, oncology, and more. Fortress Biotech Inc has consistently aimed to deliver groundbreaking medical solutions and create value for both patients and shareholders.

Who are the main competitors of Fortress Biotech in the market?

The main competitors of Fortress Biotech Inc in the market include Celgene Corporation, Novartis AG, Amgen Inc, Gilead Sciences, and Biogen Inc.

In which industries is Fortress Biotech primarily active?

Fortress Biotech Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Fortress Biotech?

The business model of Fortress Biotech Inc. focuses on acquiring, developing, and commercializing pharmaceutical and biotechnology products. As a biopharmaceutical company, Fortress Biotech Inc. collaborates with various academic and research institutions, as well as other companies, to enhance the development and commercialization of new therapies and treatments. By leveraging its extensive network and expertise, Fortress Biotech Inc. aims to provide innovative solutions to address unmet medical needs. With a diverse portfolio of product candidates targeting various disease indications, the company aims to deliver value to patients, healthcare providers, and stakeholders in the biotechnology industry.

What is the P/E ratio of Fortress Biotech 2024?

The P/E ratio cannot be calculated for Fortress Biotech at the moment.

What is the P/S ratio of Fortress Biotech 2024?

The P/S cannot be calculated for Fortress Biotech currently.

What is the AlleAktien quality score of Fortress Biotech?

The AlleAktien quality score for Fortress Biotech is 5/10.

What is the revenue of Fortress Biotech 2024?

The revenue cannot currently be calculated for Fortress Biotech.

How high is the profit of Fortress Biotech 2024?

The profit cannot currently be calculated for Fortress Biotech.

What is the business model of Fortress Biotech

Fortress Biotech Inc is a biopharmaceutical company based in the USA. It follows a unique business model, establishing or acquiring companies involved in biopharmaceutical research, development, and marketing. It has a portfolio of subsidiaries and investments operating in various areas of the healthcare industry. The company's subsidiaries and pillars consist of different disciplines, including drug development and research, diagnostics, and medical devices. Fortress Biotech utilizes the knowledge and experience of its subsidiaries to develop new products and procedures aimed at improving patient health and well-being. The company is able to serve a fast-paced market while keeping costs low by accessing publicly funded research and existing scientific infrastructure. Some of its subsidiaries include Aevitas Therapeutics, specializing in cancer therapies, and Mustang Bio, specializing in gene therapies. Fortress Biotech also has a stake in Caelum Biosciences, specializing in blood cancer treatments, and Journey Medical Corporation, specializing in dermatological diseases. The company's business model reduces the risk of failures in research and development by leveraging the knowledge and infrastructure of its subsidiaries. By collaborating and sharing resources, the company can keep costs low while still bringing innovative drugs to the market.

What is the Fortress Biotech dividend?

Fortress Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Fortress Biotech pay dividends?

The dividend cannot currently be calculated for Fortress Biotech or the company does not pay out a dividend.

What is the Fortress Biotech ISIN?

The ISIN of Fortress Biotech is US34960Q1094.

What is the Fortress Biotech WKN?

The WKN of Fortress Biotech is A14SJV.

What is the Fortress Biotech ticker?

The ticker of Fortress Biotech is FBIO.

How much dividend does Fortress Biotech pay?

Over the past 12 months, Fortress Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fortress Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Fortress Biotech?

The current dividend yield of Fortress Biotech is .

When does Fortress Biotech pay dividends?

Fortress Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fortress Biotech?

Fortress Biotech paid dividends every year for the past 0 years.

What is the dividend of Fortress Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fortress Biotech located?

Fortress Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fortress Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fortress Biotech from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did Fortress Biotech pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of Fortress Biotech in the year 2023?

In the year 2023, Fortress Biotech distributed 0 USD as dividends.

In which currency does Fortress Biotech pay out the dividend?

The dividends of Fortress Biotech are distributed in USD.

All fundamentals about Fortress Biotech

Our stock analysis for Fortress Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fortress Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.